Kostas Biliouris
Stock Analyst at Oppenheimer
(2.02)
# 3,167
Out of 4,455 analysts
424
Total ratings
40.6%
Success rate
0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $500 | $291.37 | +71.60% | 39 | Jun 25, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $4.00 | +150.00% | 2 | Jun 17, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $75 | $28.69 | +161.42% | 59 | Jun 15, 2026 | |
| DSGN Design Therapeutics | Reiterated: Buy | $21 | $13.35 | +57.30% | 4 | Jun 15, 2026 | |
| DTIL Precision BioSciences | Initiated Coverage: Buy | $20 | $7.29 | +174.35% | 21 | Jun 9, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $23 | $7.74 | +197.16% | 4 | Jun 3, 2026 | |
| EVMN Evommune | Reiterated: Buy | $50 | $25.18 | +98.57% | 3 | May 15, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.43 | +220.70% | 18 | May 12, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $37 | $16.85 | +119.58% | 37 | May 7, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Reiterated: Buy | $56.95 | $10.20 | +458.32% | 2 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.53 | +488.24% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.70 | +782.35% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $12.70 | +73.23% | 18 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $59.00 | - | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $81.18 | - | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.25 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.68 | - | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $70.24 | - | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $34.81 | - | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.341 | - | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.94 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.14 | - | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.60 | - | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.25 | - | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $54.92 | +36.56% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.82 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $303.59 | n/a | 1 | Jun 16, 2022 |
Alnylam Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $500
Current: $291.37
Upside: +71.60%
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $10
Current: $4.00
Upside: +150.00%
Legend Biotech
Jun 15, 2026
Maintained: Buy
Price Target: $75
Current: $28.69
Upside: +161.42%
Design Therapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $13.35
Upside: +57.30%
Precision BioSciences
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.29
Upside: +174.35%
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $23
Current: $7.74
Upside: +197.16%
Evommune
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $25.18
Upside: +98.57%
Prime Medicine
May 12, 2026
Reiterated: Buy
Price Target: $11
Current: $3.43
Upside: +220.70%
Sarepta Therapeutics
May 7, 2026
Reiterated: Buy
Price Target: $37
Current: $16.85
Upside: +119.58%
Satellos Bioscience Inc.
Apr 20, 2026
Reiterated: Buy
Price Target: $56.95
Current: $10.20
Upside: +458.32%
Apr 9, 2026
Reiterated: Buy
Price Target: $9
Current: $1.53
Upside: +488.24%
Mar 31, 2026
Reiterated: Buy
Price Target: $15
Current: $1.70
Upside: +782.35%
Mar 13, 2026
Reiterated: Buy
Price Target: $22
Current: $12.70
Upside: +73.23%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $59.00
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $81.18
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $3.25
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $16.68
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $70.24
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $34.81
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.341
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $20.94
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $10.14
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $11.60
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.25
Upside: -
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $54.92
Upside: +36.56%
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.82
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $303.59
Upside: n/a